digital currency fed Knowledge graph

Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.Bank of Japan: The confidence index of large manufacturers rose to the highest level since March 2022.Compared with the beginning of the personal pension system, the number of participating insurance companies has increased nearly four times, and insurance companies have become an important supplier of personal pension products. The comprehensive opening of the personal pension system will undoubtedly create a historical opportunity for the insurance industry to participate more deeply in the construction of the third pillar. (SSE)

Senior Advisor of Shi Pomao: Japan must be prepared for Trump tariffs. One of Japan's top security officials said that Japan needs to be prepared for the threat of US President-elect Trump to impose tariffs on Canada and Mexico, and adjust the supply chain to reduce the collateral damage to Japanese enterprises. Akihisa Nagashima, national security adviser to Japanese Prime Minister Shi Pomao, said that during his recent visit to the United States, he had a "frank" communication with Trump team members on tariff issues. "I realized that Japan must be ready for Trump to implement his plan," he said.Yuejiang: It is planned to sell about 40 million H shares globally through the IPO of Hong Kong stocks. It is expected to be listed on the Hong Kong Stock Exchange on December 23, and Yuejiang announced on the Hong Kong Stock Exchange on December 13 that the company plans to sell about 40 million H shares globally, with Hong Kong public offering accounting for 5% and international offering accounting for 95%. The offer price will not be higher than HK$ 20.80 per offering share, and it is currently expected to be not lower than HK$ 18.80 per offering share, with 200 shares per lot. It is expected that the shares will start trading on the Stock Exchange at 9: 00 am on Monday, December 23, 2024, Hong Kong time.Employees hide $154 million in accounts. Macy's said that internal control was ineffective. On Thursday, Macy's said that a reassessment of its financial situation showed that as of February this year, the internal control (including proper record maintenance) of the chain department store was not effective. The retailer launched an evaluation at the end of November after discovering that an employee had concealed as much as $154 million in expenses for many years. Therefore, the company postponed the release of the third quarter earnings report until December 11th. Macy's said that under the supervision of the board of directors, Tony Spring, its CEO, and Adrian Mitchell, its chief financial officer, re-evaluated the effectiveness of internal control, and pointed out that its financial report was not effective as of February 3 due to major defects. The department store chain said that it is implementing changes to improve internal control and make up for major defects.

Britain's GFK consumer confidence index was negative 17 in December, the highest since August, and negative 18 in November. The survey estimated that it was negative 18.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Market news: Trump's advisers seek to reduce or cancel banking regulators.